Table 1.
Baseline Characteristics
| Characteristic | Value (n=111) |
|---|---|
| Age, yr | 61 (52–69) |
| Male sex | 87 (78.4) |
| Hypertension | 59 (53.2) |
| Diabetes mellitus | 33 (29.7) |
| Dyslipidemia | 26 (23.4) |
| ECOG PS | |
| 0 | 97 (87.4) |
| 1 | 14 (12.6) |
| NLR | 2.59 (1.86–3.79) |
| Albumin, g/dL | 3.90 (3.60–4.30) |
| Total bilirubin, mg/dL | 0.70 (0.50–0.90) |
| Platelet count, ×109/L | 172 (118–226) |
| ALBI grade | |
| 1 | 61 (55.0) |
| 2 | 50 (45.0) |
| PT INR | 1.07 (1.01–1.11) |
| Alanine aminotransferase, IU/L | 29 (18–41) |
| C-reactive protein, mg/dL* | 0.6 (0.2–2.2) |
| α-Fetoprotein, ng/mL | 55.7 (6.6–1,762) |
| PIVKA-II, mAU/mL* | 545.5 (58.0–5,041) |
| CRAFITY score | |
| 0 | 23 (20.7) |
| 1 | 39 (35.1) |
| 2 | 13 (11.7) |
| Not available | 36 (32.5) |
| CTP score | |
| 5 | 75 (67.6) |
| 6 | 27 (24.3) |
| 7 | 9 (8.1) |
| CTP class | |
| A | 102 (91.9) |
| B | 9 (8.1) |
| BCLC stage | |
| B | 20 (18.0) |
| C | 91 (82.0) |
| Macrovascular invasion | 42 (37.8) |
| High-risk features† | 37 (33.3) |
| Vp4 PVTT | 21 (18.9) |
| Bile duct invasion | 6 (5.4) |
| Liver infiltration ≥50% | 18 (16.2) |
| Distant metastasis | |
| Lung | 29 (26.1) |
| Lymph node | 30 (27.0) |
| Bone | 19 (17.1) |
| Peritoneal seeding | 9 (8.1) |
| Adrenal | 5 (4.5) |
| None | 19 (17.1) |
| Etiology | |
| Alcohol use | 7 (6.3) |
| HBV infection | 79 (71.2) |
| HCV infection | 8 (7.2) |
| Others | 17 (15.3) |
| Prior local therapy | 67 (60.4) |
| TACE refractoriness | 21 (18.9) |
Data are presented as median (interquartile range) or number (%).
ECOG PS, Eastern Cooperative Oncology Group performance status; NLR, neutrophil-to-lymphocyte ratio; ALBI, albumin-bilirubin; PT, prothrombin time; INR, international normalized ratio; PIVKA, protein induced by vitamin K absence; CRAFITY, C-reactive protein and α-fetoprotein in immunotherapy; CTP, Child-Turcotte-Pugh; BCLC, Barcelona Liver Cancer; PVTT, portal vein tumor thrombosis; HBV, hepatitis B virus; HCV, hepatitis C virus; TACE, transarterial chemoembolization.
*Missing information on C-reactive protein for 36 patients, PIVKA-II for 1 patient; †Patients with high-risk features overlap among subcategories, with some counted in multiple categories.